VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

Volition Issues Business Review 2024
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
Volition Appoints Timothy I. Still as Chairman
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.